Taipei, Taiwan — July 12, 2026 — Anticipating 140,000 visitors, BIO Asia-Taiwan will open on July 15, 2026, in Taipei, Taiwan. This annual international conference and exhibition, established in 2019, is one of only three globally authorized BIO events, alongside the BIO International Convention and BIO-Europe, underscoring its significant standing in the global life sciences ecosystem. The event is projected to host over 900 companies across more than 2,200 booths, facilitating thousands of partnering meetings.
Strategic Focus on Advanced Therapies and Digital Health
The event's Core Exhibit Sectors will highlight critical areas for clinical advancement and regulatory consideration. The Biopharmaceuticals & Advanced Therapies sector will showcase developments in pharmaceutical products, medical devices, and cell and gene therapies. This includes innovations in biopharmaceutical R&D, novel therapeutic modalities, antibody engineering, and biologics development, alongside contract development and manufacturing organization (CDMO) services, which are crucial for accelerating drug pipelines and ensuring manufacturing quality. The Digital Health & Smart Healthcare sector will address the integration of technology in patient care, featuring digital health solutions, AI applications, ICT, and IoT technologies. This segment will explore precision medicine, smart healthcare, biomedical imaging systems, and data governance, all vital for improving diagnostic accuracy and patient management.
Collaborative Organization and Engagement Mechanisms
BIO Asia-Taiwan is jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO). Chan Chao International Co., Ltd., a professional exhibition corporation founded in 1985, is listed as an organizer for the exhibition component. This collaborative structure combines international industry leadership with local expertise. A central feature will be the BIO Partnering™ system, a one-on-one business matchmaking platform that facilitated over 8,200 meeting requests in 2024. Projections for 2025 indicated over 8,800 partnering requests. The event will also feature a comprehensive Conference Forum Series, including the Innovation Forum, Investment Summit, and Regional Collaboration Forums, alongside Company Presentations, Satellite Forums, Workshops, and dedicated Demo Days for biotech startups. The Taiwan BIO Awards and BIO Asia Award will recognize industry contributions.
Market Gateway and Growth Trajectory
The event serves as a gateway to Taiwan's biotech cluster and the broader Asia-Pacific market, targeting a diverse international audience. This includes bioindustry executives, investors from North America, Europe, and Asia, and regulatory professionals. Past editions demonstrate consistent growth; the 2024 edition saw 2,200 conference attendees and over 130,000 exhibition visitors, with more than 900 exhibitors. Projections for 2025 indicated continued expansion, with expectations of over 3,000 conference participants, 140,000 visitors, and 850+ exhibitors across 2,200+ booths. Major B2B global brands such as AbbVie, Amgen, Charles River, Cytiva, and Takeda Pharmaceutical Company Limited have previously participated or been recognized, highlighting the event's significant trade presence.
For further information or registration details, visit the official website at https://bioasiataiwan.com/en/.